Nearly 1 million bottles of heart and kidney medication recalled over foreign substance found on tablets ⁠11%

By Brie Stimson⁠0%

6/28/2026, 3:00:52 AM

BS Summary: This article contains 11 faulty reasoning types, including Framing Effect, Negativity Bias, and Ambiguity (Equivocation), with Appeal to Authority as the most egregious example at 35.9% saturation with 117 hits. Analysis detected 468 faulty-reasoning hits from 326 analyzed words, generating a BS Score of 27.5% and a BS Rank of ⁠11% (19,629 of 21,887 articles). This article is better (less manipulative) than 89.70% of the article peer group.

Nearly one million bottles of heart and kidney medication have been recalled nationwide over the possibility of a "foreign substance," according to the U.S. 
Food and Drug Administration. 
California-based Amgen, Inc. voluntarily recalled at least 944,142 bottles of Corlanor and Sensipar tablets after "unexpected foreign matter" was found "in the reserve sample of one of the identified lots," the California state Board of Pharmacy said in an alert. 
"The unexpected foreign matter was localized on the exterior tablet surface, over the coating," the board said. 
"Therefore, as a precautionary measure, all lots within expiry that were processed in AML Building 23 packaging area, where the condition occurred, are being recalled." 
The board added that hazard assessments have found it doesn’t present a clinical risk to patients and "overall patient safety risk is low." 
There have been no complaints about the issue. 
Corlanor, which is also known by the generic name ivabradine, is prescribed to treat patients with chronic heart failure and Sensipar, also known as cinacalcet hydrochloride, is mainly used to treat overactive parathyroidism in chronic kidney disease patients. 
The tablets were distributed between Oct. 28, 2021 and Dec. 
30, 2025. 
The recall includes the following presentations, according to the board: 
• Corlanor® (ivabradine) 5 mg, 60 tablets in 1 bottle; NDC 55513-800-60 
• Corlanor® (ivabradine) 5 mg, 14 tablets in 1 bottle; NDC 55513-800-99 
• Corlanor® (ivabradine) 5 mg, 60 tablets in 1 bottle; NDC 55513-810-60 
• Sensipar® (cinacalcet hydrochloride) 30 mg, 30 tablets in 1 bottle; NDC 55513-073- 30 
• Sensipar® (cinacalcet hydrochloride) 60 mg, 30 tablets in 1 bottle; NDC 55513-074- 30 
• Sensipar® (cinacalcet hydrochloride) 90 mg, 30 tablets in 1 bottle; NDC 55513-075- 30 
The FDA has characterized the recall as Class II, meaning it could "cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote." 
Article reasoning-pattern comparisonThis article: 2.5%Brie Stimson: 2.9%FoxBusiness: 4.4%Confirmation Bias2.5%This article: 0.0%Brie Stimson: 1.1%FoxBusiness: 3.4%Anchoring Bias0.0%This article: 7.4%Brie Stimson: 3.6%FoxBusiness: 4.1%Availability Heuristic7.4%This article: 0.0%Brie Stimson: 0.3%FoxBusiness: 1.1%Representativeness Heuristic0.0%This article: 0.0%Brie Stimson: 1.3%FoxBusiness: 0.7%Hindsight Bias0.0%This article: 0.0%Brie Stimson: 1.7%FoxBusiness: 3.7%Overconfidence Bias0.0%This article: 21.8%Brie Stimson: 6.4%FoxBusiness: 12.9%Framing Effect21.8%This article: 0.0%Brie Stimson: 0.4%FoxBusiness: 1.5%Loss Aversion0.0%This article: 7.7%Brie Stimson: 1.3%FoxBusiness: 1.1%Status Quo Bias7.7%This article: 0.0%Brie Stimson: 0.0%FoxBusiness: 0.2%Sunk Cost Effect0.0%This article: 16.6%Brie Stimson: 7.5%FoxBusiness: 8.8%Optimism Bias16.6%This article: 0.0%Brie Stimson: 0.6%FoxBusiness: 2.0%Pessimism Bias0.0%This article: 17.2%Brie Stimson: 8.1%FoxBusiness: 7.9%Negativity Bias17.2%This article: 0.0%Brie Stimson: 2.0%FoxBusiness: 4.5%Self-Serving Bias0.0%This article: 0.0%Brie Stimson: 0.8%FoxBusiness: 0.9%Fundamental Attribution Error0.0%This article: 0.0%Brie Stimson: 0.2%FoxBusiness: 0.2%Actor-Observer Bias0.0%This article: 0.0%Brie Stimson: 0.3%FoxBusiness: 1.7%In-Group Bias0.0%This article: 0.0%Brie Stimson: 0.0%FoxBusiness: 0.8%Out-Group Homogeneity Bias0.0%This article: 0.0%Brie Stimson: 0.7%FoxBusiness: 3.8%Halo Effect0.0%This article: 0.0%Brie Stimson: 0.0%FoxBusiness: 0.1%Horn Effect0.0%This article: 0.0%Brie Stimson: 0.0%FoxBusiness: 0.0%Dunning-Kruger Effect0.0%This article: 0.0%Brie Stimson: 0.9%FoxBusiness: 2.3%Recency Bias0.0%This article: 0.0%Brie Stimson: 0.7%FoxBusiness: 0.4%Primacy Effect0.0%This article: 0.0%Brie Stimson: 0.0%FoxBusiness: 0.1%Blind-Spot Bias0.0%This article: 0.0%Brie Stimson: 0.2%FoxBusiness: 0.8%Ad Hominem0.0%This article: 0.0%Brie Stimson: 0.0%FoxBusiness: 0.4%Straw Man0.0%This article: 35.9%Brie Stimson: 5.5%FoxBusiness: 7.2%Appeal to Authority35.9%This article: 0.0%Brie Stimson: 0.7%FoxBusiness: 1.6%False Dilemma0.0%This article: 0.0%Brie Stimson: 0.0%FoxBusiness: 1.2%Slippery Slope0.0%This article: 0.0%Brie Stimson: 0.4%FoxBusiness: 0.2%Circular Reasoning0.0%This article: 2.5%Brie Stimson: 1.5%FoxBusiness: 6.3%Hasty Generalization2.5%This article: 0.0%Brie Stimson: 0.4%FoxBusiness: 0.8%Red Herring0.0%This article: 0.0%Brie Stimson: 0.2%FoxBusiness: 1.2%Bandwagon0.0%This article: 0.0%Brie Stimson: 2.8%FoxBusiness: 6.1%Appeal to Emotion0.0%This article: 0.0%Brie Stimson: 0.0%FoxBusiness: 1.2%Begging the Question0.0%This article: 0.0%Brie Stimson: 2.7%FoxBusiness: 4.4%Post Hoc (False Cause)0.0%This article: 0.0%Brie Stimson: 0.0%FoxBusiness: 0.1%Tu Quoque0.0%This article: 2.5%Brie Stimson: 0.2%FoxBusiness: 0.4%Burden of Proof2.5%This article: 0.0%Brie Stimson: 0.0%FoxBusiness: 0.1%Appeal to Nature0.0%This article: 0.0%Brie Stimson: 0.0%FoxBusiness: 0.3%Composition/Division0.0%This article: 0.0%Brie Stimson: 0.8%FoxBusiness: 2.4%Anecdotal0.0%This article: 0.0%Brie Stimson: 0.1%FoxBusiness: 0.1%No True Scotsman0.0%This article: 16.9%Brie Stimson: 1.8%FoxBusiness: 1.9%Ambiguity (Equivocation)16.9%This article: 0.0%Brie Stimson: 0.0%FoxBusiness: 0.0%Gambler’s Fallacy0.0%This article: 0.0%Brie Stimson: 0.1%FoxBusiness: 0.1%Middle Ground0.0%This article: 0.0%Brie Stimson: 0.0%FoxBusiness: 0.1%Personal Incredulity0.0%This article: 0.0%Brie Stimson: 0.0%FoxBusiness: 0.3%Special Pleading0.0%This article: 0.0%Brie Stimson: 0.0%FoxBusiness: 0.2%Genetic Fallacy0.0%This article: 12.9%Brie Stimson: 2.8%FoxBusiness: 1.8%Unattributed Quote12.9%This article: 0.0%Brie Stimson: 2.2%FoxBusiness: 1.4%Quote-first Misdirection0.0%This article: 0.0%Brie Stimson: 2.4%FoxBusiness: 4.1%Biased Writer Voice0.0%This article: 0.0%Brie Stimson: 0.7%FoxBusiness: 1.7%Indoctrination0.0%This article: 0.0%Brie Stimson: 0.0%FoxBusiness: 0.1%Politically Left Leaning Bias0.0%This article: 0.0%Brie Stimson: 0.8%FoxBusiness: 2.1%Politically Right Leaning Bias0.0%This article: 0.0%Brie Stimson: 1.9%FoxBusiness: 4.4%Attempt to Sell a Product or S…0.0%

326 words analyzed.

Speakers

1speaker32%attributed speech221writer words
Voice mapSelect a segment to jump to its words
Writer's voice • 16 words • 0.0% coverageWriter's voice • 24 words • 0.0% coverageWriter's voice • 4 words • 0.0% coverageCalifornia state Board of Pharmacy • 40 words • 0.0% coverageCalifornia state Board of Pharmacy • 17 words • 100.0% coverageCalifornia state Board of Pharmacy • 25 words • 100.0% coverageCalifornia state Board of Pharmacy • 23 words • 0.0% coverageWriter's voice • 8 words • 0.0% coverageWriter's voice • 38 words • 0.0% coverageWriter's voice • 10 words • 0.0% coverageWriter's voice • 2 words • 0.0% coverageWriter's voice • 10 words • 0.0% coverageWriter's voice • 12 words • 0.0% coverageWriter's voice • 12 words • 0.0% coverageWriter's voice • 12 words • 0.0% coverageWriter's voice • 14 words • 0.0% coverageWriter's voice • 14 words • 0.0% coverageWriter's voice • 14 words • 0.0% coverageWriter's voice • 31 words • 0.0% coverage
100%flagged-word coverage
105 attributed words100% of attributed speech59% writer coverage
0%20.0%40.0%Unattributed Quote+40.0 ptsWriter: 0.0%California state Board of Pharmacy: 40.0%40.0%

Attribution is sentence-level. Pattern percentages are calculated only from words assigned to that voice.

Loading…
Loading…
Loading…
Loading…

Analysis

Hover over highlighted words in the article to view the associated bias or fallacy analysis.